This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COVID-19 Weekly Epidemiological Update (as of 16th January 2022). Edition 75 dated 3rd January 2022. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-updateAvailable fromhttps://www.who.int/publications/m/item/weekly-epidemiological-updateSearch in Google Scholar
COVID-19 Dashboard. Ministry of Health and Family Welfare, Government of India. 21st January 2022. Available from: https://www.mohfw.nic.inCOVID-19 Dashboard2022Available fromhttps://www.mohfw.nic.inSearch in Google Scholar
World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-ofomicron-(b.1.1.529)-sars-cov-2-variant-of-concernWorld Health Organization2021Available fromhttps://www.who.int/news/item/26-11-2021-classification-ofomicron-(b.1.1.529)-sars-cov-2-variant-of-concernSearch in Google Scholar
Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization HQ: Headquarters, Geneva, Switzerland. Update #5: 7 January 2022. Available from: https://www.who.int/publications/m/item/enhancing-readinessfor-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-statesGeneva, SwitzerlandUpdate #5: 7 January 2022. Available fromhttps://www.who.int/publications/m/item/enhancing-readinessfor-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-statesSearch in Google Scholar
SARS-CoV-2 (COVID-19 Virus) Variant of Concern (VoC) Screening and Genomic Sequencing for Surveillance. Public Health Ontario. Ontario Agency for Health Protection and Promotion. Updated on 20 December 2021. Available from: https://www.publichealthontario.ca/en/laboratory-services/test-information-index/covid-19-vocSARS-CoV-2 (COVID-19 Virus) Variant of Concern (VoC) Screening and Genomic Sequencing for SurveillanceUpdated on 20 December2021Available fromhttps://www.publichealthontario.ca/en/laboratory-services/test-information-index/covid-19-vocSearch in Google Scholar
Bhatnagar T, Chaudhuri S, Ponnaiah M, Yadav PD, Sabarinathan R, Sahay RR et al. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and Delta variant in India, 2021: A case-control study. Preprint in English. Europe PMC ID: ppcovidwho-294258BhatnagarTChaudhuriSPonnaiahMYadavPDSabarinathanRSahayRRet alSearch in Google Scholar
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.VoyseyMClemensSACMadhiSAWeckxLYFolegattiPMAleyPKet alOxford COVID Vaccine Trial Group2021397102699911110.1016/S0140-6736(20)32661-1Open DOISearch in Google Scholar
Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill. 2021;26(50). 2101146. doi:10.2807/1560-7917.ES.2021.26.50.2101146EspenhainLFunkTOvervadMEdslevSMFonagerJInghamACEpidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 202120212650210114610.2807/1560-7917.ES.2021.26.50.2101146Open DOISearch in Google Scholar
S. Kannan, P. Shaik Syed Ali, A. Sheeza. Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: a mini review. European Review for Medical and Pharmacological Sciences. 2021; 25: 8019-8022. doi: 10.26355/eurrev_202112_27653KannanS.Shaik Syed AliP.SheezaA.Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: a mini review2021258019802210.26355/eurrev_202112_27653Open DOISearch in Google Scholar
WHO COVID-19 Dashboard. Available from: https://covid19.who.int/Available fromhttps://covid19.who.int/Search in Google Scholar
MoHFW/COVID-19 States data/25th January2022/3. Release ID: 1792334. Available from: https://www.pib.gov.in/PressReleseDetail.aspx?PRID=1792330Available fromhttps://www.pib.gov.in/PressReleseDetail.aspx?PRID=1792330Search in Google Scholar
Clinical guidance for management of adult Covid-19 patients. AIIMS/ ICMR-COVID-19 National Task Force/ Joint Monitoring Group. Ministry of Health & Family Welfare, Government of India. 14th January 2022. Available from URL: https://www.mohfw.gov.in/pdf/ClinicalGuidanceforManagementofAdultCovid19Patientsupdatedason17thJanuary2022.pdfClinical guidance for management of adult Covid-19 patients14th January2022Available from URLhttps://www.mohfw.gov.in/pdf/ClinicalGuidanceforManagementofAdultCovid19Patientsupdatedason17thJanuary2022.pdfSearch in Google Scholar
Selvavinayagam TS, Somasundaram A, Nirmalson J, Kumar CAB, Aravintharaj S. S Gene target failure profiling – Declining third wave COVID-19. DPH Newsletter. 2022;2(3):1-4. Available from: https://www.tndphpm.com/wp-content/uploads/documents/Vol-2-Issue-3-February-01-2022-1.pdfSelvavinayagamTSSomasundaramANirmalsonJKumarCABAravintharajSS Gene target failure profiling – Declining third wave COVID-1920222314Available fromhttps://www.tndphpm.com/wp-content/uploads/documents/Vol-2-Issue-3-February-01-2022-1.pdfSearch in Google Scholar
Kim MK, Lee B, Choi YY, Um J, Lee KS, Sung HK, Kim Y et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea. J Korean Med Sci. 2022; 37(3):e31. doi: 10.3346/jkms.2022.37.e31.KimMKLeeBChoiYYUmJLeeKSSungHKKimYet alClinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea2022373e3110.3346/jkms.2022.37.e31Open DOISearch in Google Scholar
Kumar RM, Vivian TJW, Selvavinayagam TS, Somasundaram A, Parthipan K, Raju S et al. Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022. Indian Journal of Medical Research 2022;155(1):1-6. doi: 10.4103/ijmr.ijmr_312_22KumarRMVivianTJWSelvavinayagamTSSomasundaramAParthipanKRajuSet alClinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022202215511610.4103/ijmr.ijmr_312_22Open DOISearch in Google Scholar
Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. European Review for Medical and Pharmacological Sciences. 2021;25(24):8012-18. doi.org/10.26355/eurrev_202112_27652MeoSAMeoASAl-JassirFFKlonoffDCOmicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics20212524801218doi.org/10.26355/eurrev_202112_27652Search in Google Scholar
National Institute for Communicable Diseases. South African COVID-19 Weekly Epidemiology Brief: week 52 2021. National Institute for Communicable Diseases (NICD) South Africa; 2022. Available from: https://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-Epi-Brief_Week52.pdNational Institute for Communicable DiseasesAvailable fromhttps://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-Epi-Brief_Week52.pdSearch in Google Scholar
Sharma RP, Gautam S, Sharma P, Singh R, Sharma H, Parsoya D et al. Clinico epidemiological profile of Omicron variant of SARS CoV2 in Rajasthan. medRxiv 2022.02.11.22270698; doi: https://doi.org/10.1101/2022.02.11.22270698SharmaRPGautamSSharmaPSinghRSharmaHParsoyaDet alClinico epidemiological profile of Omicron variant of SARS CoV2 in Rajasthan202202.11.22270698;https://doi.org/10.1101/2022.02.11.22270698Open DOISearch in Google Scholar
Ewen Callaway. The race for coronavirus vaccines: a graphical guide. Nature 2000;580(7805):576.Ewen CallawayThe race for coronavirus vaccines: a graphical guide2000580780557610.1038/d41586-020-01221-ySearch in Google Scholar
WHO target product profiles for COVID-19 vaccines. April 9, 2020. Available from: https:// www.who.int/publications/m/item/who target-product-profiles-for-covid-19-vaccines.April 9, 2020. Available fromhttps://www.who.int/publications/m/item/whotarget-product-profiles-for-covid-19-vaccinesSearch in Google Scholar
Bartsch SM, O’Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am J Prev Med 2020;59: 493–503.BartschSMO’SheaKJFergusonMCet alVaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention20205949350310.1016/j.amepre.2020.06.011Search in Google Scholar
Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization HQ: Headquarters, Geneva, Switzerland. Update #5: 7 January 2022. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-statesGeneva, SwitzerlandUpdate #5: 7 January 2022. Available fromhttps://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-statesSearch in Google Scholar
Dejnirattisai W, Huo J,Zhou D, Zahradník J, Supasa P, Liu C. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Epub ahead of print bioRxiv 2021.12.03.471045; doi: https://doi.org/10.1101/2021.12.03.471045DejnirattisaiWHuoJZhouDZahradníkJSupasaPLiuCOmicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses202112.03.471045;https://doi.org/10.1101/2021.12.03.471045Open DOISearch in Google Scholar
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.The Lancet 2022:399 (10335):1618-24. doi: https://doi.org/10.1016/S0140-6736(22)00327-0MenniCValdesAMPolidoriLAntonelliMPenamakuriSet alSymptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study202239910335161824https://doi.org/10.1016/S0140-6736(22)00327-0Open DOISearch in Google Scholar
Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6.KarimSSAKarimQAOmicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic2021398103172126212810.1016/S0140-6736(21)02758-6Open DOISearch in Google Scholar